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Abstract: Diabetes is associated with obesity, generally accompanied by a chronic state of oxidative
stress and redox imbalances which are implicated in the progression of micro- and macro-complications
like heart disease, stroke, dementia, cancer, kidney failure and blindness. All these complications
rise primarily due to consistent high blood glucose levels. Insulin and glucagon help to maintain
the homeostasis of glucose and lipids through signaling cascades. Pancreatic hormones stimulate
translocation of the glucose transporter isoform 4 (GLUT4) from an intracellular location to the
cell surface and facilitate the rapid insulin-dependent storage of glucose in muscle and fat cells.
Malfunction in glucose uptake mechanisms, primarily contribute to insulin resistance in type 2
diabetes. Plant secondary metabolites, commonly known as phytochemicals, are reported to have
great benefits in the management of type 2 diabetes. The role of phytochemicals and their action on
insulin signaling pathways through stimulation of GLUT4 translocation is crucial to understand the
pathogenesis of this disease in the management process. This review will summarize the effects of
phytochemicals and their action on insulin signaling pathways accelerating GLUT4 translocation
based on the current literature.
Keywords: insulin receptor; insulin signaling pathways; PI3K; APS; GLUT4 translocation;
phytochemicals
1. Introduction
Glucose is a vital source of energy for all eukaryotic cells. Although all human cells use glucose for
their energy production, the brain utilizes 80% of consumed glucose under basal conditions. Initially,
energy is supplied by breaking down of endogenous glycogens which are stored in the liver for whole
body. Then these storages are replenished by glucose from the diet. Following carbohydrate digestion
and glucose absorption in the circulation, it is distributed among the various tissues in the body
with the stimulation of insulin secretion (Figure 1) [1]. Effect of this stimulation in transmembrane
transport of glucose into extrahepatic tissues was proposed by Goldstein and co-authors in 1949
and was extended by Morgan and co-authors in 1961 [2,3]. Inherent high glucose requirement and
rapid glucose-transport system of the brain were reported [1]. Like brain, muscle and adipose tissue
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have adapted with a highly specialized glucose-transport system for rapid uptake of glucose. This is
particularly important during exercise to meet rapidly high metabolic demand of skeletal muscle.
This rapid glucose-transport system is also crucial for insulin dependent glucose storage in muscle and
adipose tissues after a meal, which assists body to maintain normal blood glucose levels constantly.
In 1980, Suzuki and Kono proved that insulin mediates a glucose-transporting activity to the plasma
membrane from an intracellular storage site [4,5]. Glucose distribution is performed by a family of
glucose transporters (GLUTs) which act as vehicles to move sugar across the cell surface [6,7].
Molecules 2018, 23, x FOR PEER REVIEW  2 of 15 
 
requirement and rapid glucose-transport system of the brain were reported [1]. Like brain, muscle 
and adipose tissue have adapted with a highly specialized glucose-transport system for rapid uptake 
of glucose. This is particularly important during exercise to meet rapidly high metabolic demand of 
skeletal muscle. This rapid glucose-transport system is also crucial for insulin dependent glucose 
storage in muscle and adipose tissues after a meal, which assists body to maintain normal blood 
glucose levels constantly. In 1980, Suzuki and Kono proved that insulin mediates a glucose-
transporting activity to the plasma membrane from an intracellular storage site [4,5]. Glucose 
distribution is performed by a family of glucose transporters (GLUTs) which act as vehicles to move 
sugar across the cell surface  [6,7]. 
 
Figure 1. Visualization of the whole-body glucose homeostasis. Glucose homeostasis rely on the 
function of several organs as well as tissues, including the digestive system, pancreas, brain, liver, 
muscle and adipose tissue with the help of insulin stimulation, these tissues obtain energy and 
represent glucose to other parts via the available molecules such as insulin. Flaws in the detecting of 
the energy homeostasis, and the ability to respond appropriately, result in type 2 diabetes mellitus, 
major metabolic diseases. Abbreviation; FFAs: free fatty acids. 
Glucose transporter isoform 1 (GLUT1), the first identified human glucose transporter protein, 
was cloned in 1985. It is widely expressed and is not markedly compartmentalized by insulin [8]. 
However, glucose transporter isoform 4 (GLUT4) is the main insulin-responsive glucose transporter 
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Figure 1. Visualization of the whole-body glucose homeostasis. Glucose homeostasis rely on the
function of several organs as well as tissues, including the digestive system, pancreas, brain, liver,
muscle and adipose tissue with the help of insulin stimulation, these tissues obtain energy and represent
glucose to other parts via the available molecules such as insulin. Flaws in the detecting of the energy
homeostasis, and the ability to respond appropriately, result in type 2 diabetes mellitus, major metabolic
diseases. Abbreviation; FFAs: free fatty acids.
Glucose transporter isoform 1 (GLUT1), the first identified human glucose transporter protein,
was cloned in 1985. It is widely expressed and is not markedly compartmentalized by insulin [8].
However, glucose transporter isoform 4 (GLUT4) is the main insulin-responsive glucose transporter
and is located predominantly in muscle and fat cells [9]. GLUT4 was cloned and studied in several
laboratories in 1989 [10,11]. Those studies showed that GLUT4 proteins are translocated to the plasma
membrane by the action of insulin through the insulin signaling pathway. Thus, the physiological
concern of how insulin accelerates glucose uptake was transformed into the cell biological concern of
how insulin stimulates the GLUT4 membrane trafficking. Insulin enhances glucose uptake potentially
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by elevating the concentration of GLUT4 proteins at the plasma membrane, rather than by enhancing
the intrinsic activity of the transporter [12,13].
The cellular location of GLUT4 is directed by a regulated recycling process, in which endocytosis,
sorting into GLUT4 storage vesicles (GSVs), exocytosis, tethering, docking, and fusion of the proteins
are all tightly regulated. To understand the mechanism of cellular glucose uptake, two distinct fields
critical: (i) Signaling from insulin receptor and (ii) GLUT4 translocation. Not surprisingly, identifying
the molecules that correlate insulin signaling to the GLUT4 trafficking has been a major focus of
research [14]. By commencing several signaling pathways, insulin controls energy metabolism that
regulates cells growth and survival, as well as uptake, synthesis and hydrolysis of glycogen, proteins
and lipids [15]. Some of these signaling pathways, including the mammalian target of rapamycin
complex 1 (mTORC1) and extracellular signal-regulated kinase (ERK) pathway, are not large enough in
controlling of transport of glucose [16,17]. As an alternative, adaptor protein with pleckstrin homology
and Src homology 2 (SH2) domain (APS) and a phosphoinositide 3-kinase (PI3K) dependent insulin
signaling pathways are required by glucose transport in adipose tissue. Src (abbreviated form of
sarcoma) is a proto-oncogene encoding one of tyrosine kinases [18]. Of note, the PI3K dependent
insulin signaling pathway for glucose uptake in muscle is fairly well-known, although the necessity
for the APS-dependent insulin signaling pathway in this particular tissue is still elusive. All these
pathways together, clarify the delivery efficiency of GLUT4 to the cell surface by assembling signaling
stage at the plasma membrane that are comprised of protein kinases, lipids, adaptor proteins, small
GTPases (enzymes that hydrolyze guanosine triphosphate, GTP) and lipid kinases. These signaling
pathways involve the compartmentalizing mechanism in regulation of GLUT4 cycling. However, this
GLUT4 cycling can also be overstimulated in case of various cancers, like plasma cell malignancy,
multiple myeloma, etc. To treat such condition, several studies have been performed to develop GLUT4
antagonist synthetically [19,20]. The insulin hormone is responsible for glucose homeostasis which
is released by the pancreatic β-cells [21]. Inappropriate insulin utilization, leading cause of insulin
resistance, is a defective condition characterized by the failure of cell response to standard circulating
insulin levels [22] Phytochemicals could be possible alternatives in treatment of type 2 diabetes mellitus
or supports in current treatment used. They might also be more effective and have less side-effects
than the present medications as well as reduce the risks of the disease. One positive aspect is that large
amounts of phytochemicals are already consumed in the daily diet. There are plenty of phytochemicals
which are discussed in literature based on their effects against insulin resistance or type 2 diabetes.
There are many plants which have been used since ancient times in preventing the conditions which are
associated with insulin resistance [23]. Though the possible mechanism is not absolutely understood,
numerous studies are being conducted to reveal the different signaling pathways by which various
phytochemicals act. The main insulin-responsive GLUT isoform is GLUT4 which is predominantly
present in skeletal muscle and adipose tissues. We, therefore, have discussed on the insulin signaling
system with GLUT4, the recent understanding of how GLUT4 are compartmentalized by insulin
signaling pathways and the role of phytochemicals on these signaling pathways in GLUT4 translocation
for prophylaxis and treatment of insulin resistance in GLUT4 located tissues.
2. Phytochemicals
Medicinal plants have been the basic source of drugs from ancient times and are used extensively
as crude drugs for treating various diseases. Some 1–10% of the estimated 250,000 to 500,000 species
of plants on Earth are used by humans [24]. Based on the recognized bioactive phytochemicals,
polyphenols are the most widespread compounds due to antioxidant and antidiabetic effects of
these compounds. The role of polyphenols in glucose homeostasis and carbohydrate metabolism
has been well studied and investigated in in-vitro and in-vivo models as well as in some clinical
experiments. Some reported antidiabetic effects of phytochemicals through insulin signaling pathways
by accelerating GLUT4 translocation are listed in Table 1.
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Table 1. Some reported antidiabetic effects of phytochemicals on insulin signaling pathways
accelerating glucose transporter isoform 4 (GLUT4).
Phytochemicals Plants Effects on Insulin Signaling PathwaysAccelerating GLUT4 References
Resveratrol Numerous plants
Induces AKT and VEGF as well as the expression of
GLUT4 in muscle of STZ-induced diabetic rats via
PI3K-AKT pathways
[25]
Gallotannins Capparis moon Increases GLUT4 and PI3K mRNA expression in theL6 cells [26]
3β-taraxerol Mangifera indica
Activates glucose transport through the translocation
of GLUT4, mediating by PI3K dependent activation
of AKT protein
[27]
Astragalus polysaccharide Astragalus membranaceus Regularizes insulin-stimulated PKB-Ser473phosphorylation and GLUT4 translocation [28]
Cyanidin-3-O-β-glucoside and
protocatechuic acid Numerous plants
Insulin-like activity enhancing GLUT4 translocation
and adiponectin secretion [29]
Daidzein Glycine max Activates AMPK followed by GLUT4 translocationand enhances glucose homeostasis [30]
Iridoid, catalpol, specioside
and verminoside Kigelia pinnata Stimulation of GLUT4 trafficking to cell surface [31]
Gallic acid Myriophyllum spicatum
Decreases blood glucose and also enhances glucose
uptake through the compartmentalization of GLUT4
to the plasma membrane
[32]
Berberine and vanillic acid Berberis aristata andnumerous plants
Improves the translocation of GLUT4 via
AMPK-dependent pathway [33]
Mangiferin Salacia oblonga
Enhances the GLUT4 proteins expression and
translocation of this glucose transporter to the
surface of L6-myocites and 3T3-adipocytes
[34]
Abbreviations: AKT: Protein kinase B (also known as PKB), VEGF: Vascular endothelial growth factor, STZ:
Streptozotocin, PI3K: Phosphoinositide 3-kinase, AMPK: 5' adenosine monophosphate-activated protein kinase.
The hypoglycemic effects of polyphenols are chiefly ascribed to lowering the uptake of
carbohydrates in the intestine, affecting the glucose metabolism by altering enzyme activities,
improving β-cell function and insulin action, initiating insulin release and antioxidant as well
as anti-inflammatory effects. [35–37]. The impacts of the naturally occurring components on the
expression of genes are ongoing intensive research to stipulate the mechanisms and novel targets by
which these active constituents act as anti-diabetic. Polyphenolic phytochemicals may stimulate gene
expressions involved in the occurrence of type 2 diabetes, such as genes controlling the transportation
of glucose, release of insulin and its function, antioxidant effect, inflammation, vascular functions,
lipid metabolism and thermogenic or other probable mechanisms [25,38,39]. Several phytochemicals
have been investigated in diabetic rodent models to disclose gene expression data, insulin signaling
pathways and glucose transporters data of different target tissues. Some phytochemicals play
an important role in insulin signaling pathways and their impact on GLUT4 in regulating glucose
uptake. For instance, resveratrol has been observed to induce AKT (also known as protein kinase B) and
VEGF (vascular endothelial growth factor) in streptozotocin (STZ)-induced diabetic rat myocardium
compared to non-diabetic animals as well as to increase the expression of GLUT4 in muscle of
STZ-induced diabetic rats via PI3K-AKT pathways. Pathologically, lower GLUT4 induction was found
in diabetic’s state [25] Valuable effects of polyphenols on maintenance of plasma glucose in diabetics
are summarized in Figure 2.
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Figure 2. The hypoglycemic effects of phytochemicals are chiefly ascribed to lower the uptake of
carbohydrates in intestine affecting the glucose metabolism by applying an alteration in the enzyme
activities, β-cell function betterment and insulin action i provement, insulin release initiation and
antioxidant as well as anti-infla matory characteristic of these components. SGLT: Sodium-Glucose
Linked Transporter.
GLUT Proteins: Structure and Function
The GLUTs (or SLC2A), member of the solute carrier family, are membrane transport proteins
that facilitate glucose transportation over plasma membrane, composed of more than five thousand
members in all three kingdoms [40,41]. The presence of these transporters in all phyla suggests that
glucose is a vital source of energy for all forms of life. Many people believe that there are 14 GLUTs
in humans [9] and these 14 isoforms are classified into class I (GLUTs 1–4, 14), class II (GLUTs 5,
7, 9 and 11) and class III (GLUTs 6, 8, 19, 12 and 13). GLUTs are the main regulators of glucose
homeostasis in the body and every cell type of the body consists of at least one GLUT isoform. In order
to insulin dependent glucose transport, GLUT4 isoform mainly needs to be translocated from an
intracellular site to the plasma membrane to enhance glucose uptake. Therefore, GLUT4 is responsible
for insulin-stimulated glucose uptake [42,43]. This transporter plays a major role in the maintenance
of plasma glucose, since it is primarily expressed in tissues associated with insulin mediated glucose
uptake, such as skeletal muscle and adipose tissues [43]. Since GLUT4 is dependent on insulin for
the uptake of glucose and its impairment can cause insulin resistance and the aim of this review is
to discuss the insulin signaling pathway, more emphasis has been given on this glucose transporter
protein. In Table 2, reported features of GLUT4 including others of class I glucose transporters
are described.
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Table 2. Characteristics of class I glucose transporters (GLUTs 1–4) [9,44,45].
Isoform Gene Chromosome Tissue Distribution Substrate Function
GLUT1 SLC2A1 1p34.2 Ubiquitous, erythrocytes Glucose, galactose,dehydroacetic acid
Glucose uptake of tissues, glucose transportation
through blood barriers into tissues
GLUT2 SLC2A2 3q26.2 Brain, intestine, liver,beta-cells, kidney
Glucose, fructose, galactose,
dehydroacetic acid,
glucosamine
Facilitated transporter of glucose and fructose,
low attraction with large capacity
GLUT3 SLC2A3 12p13.31 Brain Glucose, galactose,dehydroacetic acid
Neuronal uptake, facilitated transporter of
glucose with strong affinity
GLUT4 SLC2A4 17p13 Skeletal and heartmuscles, adipocytes Glucose, dehydroacetic acid
Insulin dependent transporters, responsible for
insulin resistance
3. GLUT-4 Targets Insulin Signaling Pathway
Insulin signaling coordinates GLUT4 mobilization from intracellular membrane particles, GSVs
recognition at plasma membrane, at finally these two membranes are fused through multiple engaging
of GTPases which start cycling between an ‘active’ GTP-bound conformation and they facilitate an
‘inactive’ guanosine diphosphate (GDP)-bound state and their biological effects. Multiple components
of the compartmentalizing machinery interact with active GTPases to confer alignment and specificity
in membrane flow [46]. Furthermore to small GTPases, insulin signaling directly targets motor proteins,
fusion-regulating proteins and membrane tethers which propose the insulin conducts several phases
in the GLUT4 trafficking route to elevate the concentration of the transporter on the cell surface.
The insulin signaling pathways increase the levels of GLUT4 of plasma membrane mostly by raising
exocytosis of GSVs. Yet, studies show insulin might also affect the endocytosis, sorting and formation
of GSVs in the GLUT4 membrane trafficking [47,48].
3.1. Insulin Signaling Pathway and GLUT4 Trafficking
Insulin express its action upon its connection to insulin receptor (IR), which is a type of tyrosine
kinase comprised of two extracellular α subunits considered as insulin binding sites and two
cytoplasmic β subunits. Attachment of α subunits to the insulin hormone induces the phosphorylation
of β subunits and transferring signals in the entire membrane. This event activates the intracellular
tyrosine kinase domain of the β subunit [13] leading to auto-phosphorylation of tyrosine residues
in several regions of this subunit, including juxtamembrane region, regulatory loop and C-terminal
(Figure 3) [49,50].
Then, activated IR phosphorylates phosphotyrosine binding domains on the intracellular
substrates, including insulin receptor substrate (IRS) family, Gab-1, CBL, APS and Shc (adapter
protein) isoforms and signal regulatory protein (SIRP) family members [13,51]. Linkage of insulin to
its receptor which induces tyrosine kinase operation as a key factor involved in the insulin activity.
Mutations in the Adenosine triphosphate (ATP) binding domain abolish ATP binding, resulting in
shutdown of kinase activity and insulin signaling [52].
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Figure 3. Insulin activates insulin receptor. Subjection of insulin to its receptor brings in the action
of insulin and activates insulin receptor which is a type of tyrosine kinase and is comprised of
two extracellular α subunits and two cytoplasmic β subunits. Attachment of α subunits to the
insulin hormone induces the phosphorylation of β subunits and transferring signals in the entire
membrane and activates the intracellular tyrosine kinase domain of the β subunit. Insulin binding
activates the tyrosine kinase which leads to autophosphorylation of tyrosine residues in several
regions of the intracellular β-subunit, including juxtamembrane region, regulatory loop and C-terminal.
The activated IR then phosphorylates phosphotyrosine binding domains on intracellular substrates.
Abbreviations: ATP-Adenosine triphosphate, ADP- Adenosine diphosphate, IR- Insulin Receptor,
NPEY; Asn-Pro-Glu-Tyr-Motif.
3.2. Activation of PI3K Pathway
Binding of insulin to IR activates the PI3K-mediated insulin signaling pathway, which involves
and phosphorylates IRS proteins [15]. Afterwards, IRS molecules build a connection with
p85 regulatory subunit of I PI3K class by acting as docking sites for the SH2 domain.
Activity of IRS molecules together with PI3K activates and the successive formation of
phosphatidylinositol-3,4,5-trisphosphate (PIP3) from phosphatidylinositol-4,5-bisphosphate (PIP2)
at the plasma membrane (Figure 4a). In turn, PIP3 acts as a docking site for several PH
domain-containing serine/threonine kinases which are associated in glucose uptake, including
phosphoi ositide-dependent kinase 1 ( D 1) and AKT [53]. Through dual serine/thre nine
phos rylation, PDK1 and mTORC2 activate AKT. The mostly stud ed targets of AKT are the
RAB GAP AS160 and RAL-GAP complex (RGC), belongs to the family of small GTPases. These small
GTPases are involved in GLUT4 vesicle translocation, directed t the la ma membrane [54,5 ].
Synip and CDP138, categorized as the soluble N ethylmaleimide-sensitive factor attachment protein
receptor (SNARE) regulatory proteins, are direct substrates for AKT and regulate GLUT4 v sicle fus on
with the plasma membrane [47,56].
Studies in the presence of IRS/AKT inhibit rs or dominant-negative IRS/AKT have reve led th
necessity of IRS molecules in addition to AKT in the absorption of glucose [57,58]. The active AKT over
expres ion can significantly but not entirely emulate insulin efficiency [59,60]. AKT, a focal axis links
insulin signals to the modulator proteins of GLUT4 trafficking. Molecular studies that investigated
GLUT4 trafficking in the knockout or knockdown of AKT constructs demonstrated that kinase affects
the exocytic domain of the GLUT4 trafficking itinerary, by targeting and fusion of GLUT4 containing
vesicles and regulating the translocation [54,61]. The experimentation for AKT targets in muscle and
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adipocytes continue, probably gives further intuition into the definite phases of GLUT4 trafficking
which is regulating by this kinase.
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ic is a guanine nucleotide exchange factor (GEF). C3G in turn activates TC10 which is originated in
lipid rafts in the plasma membrane. Active TC10 (a member of small GTP-binding protei s) regulates
GLUT4 vesicle exocytosis by interacting with several effector proteins. One TC10 binding protein, CIP4,
recruits a stable complex with the RAB GEF GAPEX5. This regulates GLUT4 vesicles retention and
translocation. Another EXO70 (a subunit of exorcist complex), TC10 effector protein and a subunit of
the exocyst tethering complex, has been implicated in GLUT4 vesicle targeting.
3.3. Activation of APS Pathway
Insulin binding to the activated insulin receptor initiates an APS-dependent insulin signaling
cascades by recruiting and tyrosine phosphorylation of the adaptor protein APS [62]. Upon the addition
of phosphate group to IR, APS activate a complex following the c-CBL-associated protein (CAP) and
activation of proto-oncogene c-CBL [63,64]. This causes IR-catalyzed tyrosine phosphorylation of
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c-CBL which in turn activates signal transduction molecules such as CRK, which is in involved with the
guanine nucleotide exchange factor (GEF) protein cyanidin 3-glucoside (C3G) (Figure 4b) [65]. C3G then
activates TC10, a member of the RHO-family of small GTPases [66,67] originated from lipid rafts in
the plasma membrane. Active TC10 regulates GLUT4 vesicle exocytosis by interacting with several
effector proteins. One TC10 binding protein, CDC42 interacting protein 4 (CIP4), recruits a constant
complex with the RAB GEF GAPEX5. This regulates the activity of RAB5 family GTPases, which are
involved in GLUT4 vesicles retention and translocation. Another EXO70, TC10 effector protein and
a subunit of the exocyst tethering complex, has been implicated in GLUT4 vesicle targeting [47].
Disrupting individual components of the PI3K-mediated or the APS-mediated insulin signaling
pathways in adipocytes, either by proteins inhibitors or with small interfering RNA (siRNA)-mediated
knockdown which inhibits glucose uptake and GLUT4 exocytosis, [47,57,68] suggests that these
pathways control the GLUT4 trafficking machinery. The PI3K signaling pathway is important
for GLUT4 exocytosis in muscle cells. The need for an APS signaling route in the absorption
of glucose upon the stimulation by insulin is uncertain due to conflicting siRNA and mouse
knockout studies. In a study, low efficiency of TC10α regardless of TC10β in 3T3-L1 adipocytes
induces a restricted suppression in the glucose intake in the response to insulin release and
GLUT4 trafficking [68]. However, in another study, CAP, a protein of APS signaling pathway,
seems to be crucial in insulin signaling. CAP is significantly induced during adipocyte
differentiation and is regulated transcriptionally by the thiazolidinedione family of insulin-sensitizing
peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists [69]. In this line, expression
of a dominant-interfering CAP mutant in another study completely blocked both insulin-stimulated
glucose uptake and GLUT4 trafficking [51], but the siRNA mediated knockdown of c-CBL and
CAP proteins did not exert any substantial effect on insulin-stimulated glucose uptake or GLUT4
trafficking [70,71]. Together, APS signaling pathway plays a relatively controversial role at the different
molecular targets in insulin-stimulated GLUT4 trafficking.
4. Phytochemicals and Insulin Signaling Pathway
Insulin sensibility in mice with diabetes was improved upon the administration of
methylswertianin and bellidifolin phytochemicals [72]. The mechanism of action of these
phytochemicals is to increase expression of IR, IRS-1 and PI3K proteins which are involved in the
insulin signaling pathways. Moreover, both phytochemicals are capable of decreasing the activity of
glucokinase (GK) and increasing glucose-6-phosphatase (G6Pase) activity, stimulating beta cells in
the pancreas to release insulin. Similarly, it was demonstrated that administration of two gallotannins
has increased the mRNA expression of GLUT4 and PI3K in the L6 cells [26]. The bioactive compound,
3β-taraxerol exhibited its function following by glucose transport and its preservation upon glucose
consumption and glycogen formation. This study revealed that triterpenoid activated glucose transport
through the translocation of GLUT4, was mediated by PI3K dependent activation of AKT protein [27].
In another study, Astragalus polysaccharide improved glucose homeostasis and enhanced insulin
sensitivity in skeletal muscle of type 2 diabetic mice. The mechanism underlying improvement of
insulin sensitivity by Astragalus polysaccharide is to regularize the insulin-stimulated PKB-Ser473
phosphorylation and GLUT4 translocation [28]. Cyanidin-3-O-β-glucoside and protocatechuic acid
possess insulin-like activity in human adipocytes. These phytochemicals increase glucose uptake by
enhancing GLUT4 translocation and adiponectin secretion that causes probable improved activity of
PPAR-γ [29]. Daidzein activates adenosine monophosphate-activated protein kinase (AMPK) followed
by GLUT4 translocation to plasma membrane of muscle cells and enhances glucose homeostasis in type
2 diabetic mice [30]. Iridoid, catalpol, specioside and verminoside showed substantial GLUT4 excitation
in the superficial layer of cell to facilitate intracellular glucose uptake [31]. Gallic acid decreases blood
glucose in diabetic rats [32] and also enhances glucose uptake through the compartmentalization of
GLUT4 to the plasma membrane in adipocytes, isolated from STZ-treated rats [73]. Besides, it has
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been found that quercetin decreases the expression of the Na+-dependent glucose transporter (SGLT1),
inhibiting the intestinal glucose absorption in CaCo-2/15 cell lines [74].
Protein tyrosine phosphatase 1B (PTP1B) is an antagonist of the insulin transduction pathway,
moreover, dephosphorylated insulin receptor tyrosine kinase (IRTK) and IRS result in the suppression
of insulin transduction pathway. The PTP1B knock-out mice exhibited enhanced insulin sensitivity
in muscles and liver [75] which revealed an option for the anti-diabetic function of specific PTP1B
inhibitors [76]. Ursolic acid and oleanolic acid were identified as competitive PTP1B inhibitors,
indicating higher expression of phosphorylated insulin receptor and glucose adsorption [77,78].
Berberine and vanillic acid significantly improve GLUT4 translocation via AMPK-dependent pathway,
whereas arecoline does the same via the PPAR-γ pathway [33] Besides, the fungal metabolite,
demethylasterrriquinone-B, could directly stimulate IRTK, AKT and ERK pathways, apply glucotropic
effects of insulin with no mitogenic effect exertion [79,80].
Apart from the above bioactive compounds, there are many more phytochemicals other than
flavonoids have been reported for their anti-hyperglycemic effects [81–83]. Piperine, pipernonaline
and dehydropipernonaline are alkaloid compounds extracted from Piper retrofractum that trigger
activation of AMPK signaling pathway and the PPAR-γ protein [84,85]. Another study showed that
ellagitannins, a tannin phytochemical, restrain α-glucosidase enzymes [86]. In addition, thiosugars
like kotalanol [87] and salacinol [88], also inhibit α-glucosidase enzymes. This inhibitory effect of
α-glucosidase enzymes is sometimes analogous to the inhibitory effect of standard drugs, acarbose and
voglibose [87,88]. Another anti-hyperglycemic plant biomolecule, mangiferin, is a xanthone compound.
In the Salacia oblonga extract, the presence of mangiferin enhanced the GLUT4 proteins expression
and translocation of this glucose transporter to the surface of L6-myocytes and 3T3-L1 adipocytes,
consequently, increasing glucose uptake by the cells [34].
5. Conclusions
Understanding the cellular substrates of insulin signaling pathways and their effect on GLUT4
compartmentalization supports the intracellular itinerary of glucose uptake by predominantly
GLUT4-containing tissues in both normal and diabetic condition and the role of phytochemicals.
Therapeutically, the glucose transporter isoform GLUT4 could be a crucial target to treat
insulin resistance, since GLUT4 is an insulin-dependent isoform which is responsible for most
insulin-stimulated glucose uptake. Naturally occurring bioactive compounds such as phytochemicals,
known as cures for insulin resistance and suppression of the disease, need more research attention.
A number of phytochemicals evaluated for their antidiabetic properties in insulin signaling pathways
and GLUT4 protein have been discussed and reviewed here. Some of these phytochemicals display
very significant effects. Dietary consumption of bioactive natural compounds reduces the risk of
insulin resistance due to GLUT4 impairment in skeletal muscle and adipose tissues. Additionally,
phytochemical therapy perhaps offers a new therapeutic approach in pharmacological studies to cure
type 2 diabetes or facilitate the greater effect of current treatments.
Acknowledgments: This review is a part of Taylor’s University Flagship Research under the theme “Ageing and
Quality of Life” (Project No: TUFR/2017/002/01). We would like to thank P.T. Thomas, Executive Dean of the
Faculty of Health and Medical Sciences for his encouragement and support.
Author Contributions: A.S.M.S and A.A. designed and wrote most of the manuscript. H.K., N.K., A.A.H.,
helped in writing specific part of the manuscript. C.F.H. created the images, finally revised and edited the
manuscript. All the authors reviewed and approved the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
Molecules 2018, 23, 258 11 of 15
References
1. Ahn, M.Y.; Katsanakis, K.D.; Bheda, F.; Pillay, T.S. Primary and essential role of the adaptor protein APS
for recruitment of both c-Cbl and its associated protein CAP in insulin signaling. J. Biol. Chem. 2004, 279,
21526–21532. [CrossRef] [PubMed]
2. Goldstein, M.; Levine, R.; Klein, S.; Huddlestun, B. The action of insulin on the distribution of galactose in
eviscerated nephrectomized dogs. J. Biol. Chem. 1949, 179, 985.
3. Morgan, H.E.; Henderson, M.J.; Regen, D.M.; Park, C.R. Regulation of glucose uptake in muscle. I. The effects
of insulin and anoxia on glucose transport and phosphorylation in the isolated, perfused heart of normal
rats. J. Biol. Chem. 1961, 236, 253–261. [PubMed]
4. Suzuki, K.; Kono, T. Evidence that insulin causes translocation of glucose transport activity to the plasma
membrane from an intracellular storage site. Proc. Natl. Acad. Sci. USA 1980, 77, 2542–2545. [CrossRef]
[PubMed]
5. Cushman, S.W.; Wardzala, L.J. Potential mechanism of insulin action on glucose transport in the isolated
rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J. Biol.
Chem. 1980, 255, 4758–4762. [PubMed]
6. Joost, H.G.; Bell, G.I.; Best, J.D.; Birnbaum, M.J.; Charron, M.J.; Chen, Y.T.; Doege, H.; James, D.E.; Lodish, H.F.;
Moley, K.H.; et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am. J.
Physiol. Endocrinol. Metab. 2002, 282, 974–976. [CrossRef] [PubMed]
7. Bouche, C.; Serdy, S.; Kahn, C.R.; Goldfine, A.B. The cellular fate of glucose and its relevance in type
2 diabetes. Endocr. Rev. 2004, 25, 807–830. [CrossRef] [PubMed]
8. Mueckler, M.; Caruso, C.; Baldwin, S.A.; Panico, M.; Blench, I. Sequence and structure of a human glucose
transporter. Science 1985, 229, 941–945. [CrossRef] [PubMed]
9. Mueckler, M.; Thorens, B. The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 2013, 34,
121–138. [CrossRef] [PubMed]
10. James, D.E.; Strube, M.; Mueckler, M. Molecular cloning and characterization of an insulin-regulatable
glucose transporter. Nature 1989, 338, 83–87. [CrossRef] [PubMed]
11. Birnbaum, M.J. Identification of a novel gene encoding an insulin-responsive glucose transporter protein.
Cell 1989, 57, 305–315. [CrossRef]
12. Furtado, L.M.; Somwar, R.; Sweeney, G.; Niu, W.; Klip, A. Activation of the glucose transporter GLUT4 by
insulin. Biochem. Cell Biol. 2002, 80, 569–578. [CrossRef] [PubMed]
13. Watson, R.T.; Kanzaki, M.; Pessin, J.E. Regulated membrane trafficking of the insulin-responsive glucose
transporter 4 in adipocytes. Endocr. Rev. 2004, 25, 177–204. [CrossRef] [PubMed]
14. Simpson, F.; Jonathan, P.W.; David, E.J. GLUT4—At the cross roads between membrane trafficking and
signal transduction. Traffic 2001, 2, 2–11. [CrossRef] [PubMed]
15. Saltiel, A.R.; Kahn, C.R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001,
414, 799–806. [CrossRef] [PubMed]
16. Lazar, D.F.; Wiese, R.J.; Brady, M.J.; Mastick, C.C.; Waters, S.B.; Yamauchi, K.; Pessin, J.E.; Cuatrecasas, P.;
Saltiel, A.R. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose
utilization by insulin. J. Biol. Chem. 1995, 270, 20801–20807. [CrossRef] [PubMed]
17. Polak, P.; Cybulski, N.; Feige, J.N.; Auwerx, J.; Rüegg, M.A.; Hall, M.N. Adipose-specific knockout of raptor
results in lean mice with enhanced mitochondrial respiration. Cell Metab. 2008, 8, 399–410. [CrossRef]
[PubMed]
18. Larsen, C.J. The Nobel Prize in physiology and medicine 1989. J. Michael Bishop and Harold E. Varmus.
Pathol. Biol. (Paris) 1989, 37, 1077–1078.
19. Mishra, R.K.; Wei, C.; Hresko, R.C.; Bajpai, R.; Heitmeier, M.; Matulis, S.M.; Nooka, A.K.; Rosen, S.T.;
Hruz, P.W.; Schiltz, G.E.; et al. In Silico Modeling-based Identification of Glucose Transporter 4
(GLUT4)-selective Inhibitors for Cancer Therapy. J. Biol. Chem. 2015, 290, 14441–14453. [CrossRef] [PubMed]
20. Wei, C.; Bajpai, R.; Sharma, H.; Heitmeier, M.; Jain, A.D.; Matulis, S.M.; Nooka, A.K.; Mishra, R.K.; Hruz, P.W.;
Schiltz, G.E.; et al. Development of GLUT4-selective antagonists for multiple myeloma therapy. Eur. J.
Med. Chem. 2017, 139, 573–586. [CrossRef] [PubMed]
21. Sesti, G. Pathophysiology of insulin resistance. Best Practice. Res. Clin. Endocrinol. Metab. 2006, 20, 665–679.
22. Berg, J.M.; Tymoczko, J.L.; Stryer, L. Biochemistry, 5th ed.; W H Freeman: New York, NY, USA, 2002.
Molecules 2018, 23, 258 12 of 15
23. Soumyanath, A. Traditional Medicines for Modern Times—Antidiabetic Plants; CRC Press: Boca Raton, Floria,
USA, 2005.
24. Borris, R.P. Natural products research: Perspectives from a major pharmaceutical company. J. Ethnopharmacol.
1996, 51, 29–38. [CrossRef]
25. Das, U.N. GLUT-4, tumor necrosis factor, essential fatty acids and daf-genes and their role in insulin
resistance and non-insulin dependent diabetes mellitus. Prostaglandins Leukot. Essent. Fat. Acids 1999, 60,
13–20. [CrossRef]
26. Kanaujia, A.; Duggar, R.; Pannakal, S.T.; Yadav, S.S.; Katiyar, C.K.; Bansal, V.; Anand, S.; Sujatha, S.;
Lakshmi, B.S. Insulinomimetic activity of two new gallotannins from the fruits of Capparis moonii. Bioorg.
Med. Chem. 2010, 18, 3940–3945. [CrossRef] [PubMed]
27. Sangeetha, K.N.; Sujatha, S.; Muthusamy, V.S.; Anand, S.; Nithya, N.; Velmurugan, D.; Balakrishnan, A.;
Lakshmi, B.S. 3β-taraxerol of Mangifera indica, a PI3K dependent dual activator of glucose transport and
glycogen synthesis in 3T3-L1 adipocytes. Biochim. Biophys. Acta 2010, 1800, 359–366. [CrossRef] [PubMed]
28. Liu, M.; Wu, K.; Mao, X.; Wu, Y.; Ouyang, J. Astragalus polysaccharide improves insulin sensitivity in KKAy
mice: Regulation of PKB/GLUT4 signaling in skeletal muscle. J. Ethnopharmacol. 2010, 127, 32–37. [CrossRef]
[PubMed]
29. Scazzocchio, B.; Varì, R.; Filesi, C.; D’Archivio, M.; Santangelo, C.; Giovannini, C.; Iacovelli, A.; Silecchia, G.;
Volti, G.; Galvano, F.; et al. Cyanidin-3-O-b-Glucoside and Protocatechuic Acid Exert Insulin-Like Effects
by Upregulating PPARg Activity in Human Omental Adipocytes. Diabetes 2011, 6, 2234–2244. [CrossRef]
[PubMed]
30. Cheong, S.H.; Furuhashi, K.; Ito, K.; Nagaoka, M.; Yonezawa, T.; Miura, Y.; Yagasaki, K. Daidzein promotes
glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and
improves glucose homeostasis in Type 2 diabetic model mice. J. Nutr. Biochem. 2014, 25, 136–143. [CrossRef]
[PubMed]
31. Khan, M.F.; Dixit, P.; Jaiswal, N.; Tamrakar, A.K.; Srivastava, A.K.; Maurya, R. Chemical constituents of
Kigelia pinnata twigs and their GLUT4 translocation modulatory effect in skeletal muscle cells. Fitoterapia
2012, 83, 125–129. [CrossRef] [PubMed]
32. Latha, R.C.R.; Daisy, P. Insulin-secretagogue, antihyperlipidemic and other protective effects of gallic acid
isolated from Terminalia bellerica Roxb. in streptozotocin-induced diabetic rats. Chem. Biol. Interact. 2011, 189,
112–118. [CrossRef] [PubMed]
33. Prabhakar, P.K.; Doble, M. Effect of Natural Products on Commercial Oral Antidiabetic Drugs in Enhancing
2-Deoxyglucose Uptake by 3T3-L1 Adipocytes. Ther. Adv. Endocrinol. Metab. 2011, 3, 103–114. [CrossRef]
[PubMed]
34. Girón, M.D.; Sevillano, N.; Salto, R.; Haidour, A.; Manzano, M.; Jiménez, M.L.; Rueda, R.; López-Pedrosa, J.M.
Salacia oblonga extract increases glucose transporter 4-mediated glucose uptake in L6 rat myotubes: Role of
mangiferin. Clin. Nutr. 2009, 28, 565–574. [CrossRef] [PubMed]
35. Iwai, K.; Kim, M.Y.; Onodera, A.; Matsue, H. α-Glucosidase inhibitory and antihyperglycemic effects of
polyphenols in the fruit of Viburnum dilatatum Thunb. Agric. Food Chem. 2006, 54, 4588–4592. [CrossRef]
[PubMed]
36. Iwai, K. Antidiabetic and antioxidant effects of polyphenols in brown alga Ecklonia stolonifera in genetically
diabetic KK-Ay mice. Plant Foods Hum. Nutr. 2008, 63, 163–169. [CrossRef] [PubMed]
37. Cabrera, C.; Artacho, R.; Giménez, R. Beneficial effects of green tea—A review. J. Am. Coll. Nutr. 2006, 25,
79–99. [CrossRef] [PubMed]
38. Thirunavukkarasu, M.; Penumathsa, S.V.; Koneru, S.; Juhasz, B.; Zhan, L.; Otani, H.; Bagchi, D.; Das, D.K.;
Maulik, N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide,
thioredoxin, and heme oxygenase. Free Radic. Biol. Med. 2007, 43, 720–729. [CrossRef] [PubMed]
39. Moskaug, J.Ø.; Carlsen, H.; Myhrstad, M.; Blomhoff, R. Molecular imaging of the biological effects of
quercetin and quercetin-rich foods. Mech. Ageing Dev. 2004, 125, 315–324. [CrossRef] [PubMed]
40. Thorens, B.; Mueckler, M. Glucose transporters in the 21st Century. Am. J. Physiol. Endocrinol. Metab. 2010,
298, 141–145. [CrossRef] [PubMed]
41. Pao, S.S.; Paulsen, I.T.; Saier, M.H. Major facilitator superfamily. Microbiol. Mol. Biol. Rev. 1998, 62, 1–34.
[PubMed]
Molecules 2018, 23, 258 13 of 15
42. Bryant, N.J.; Goovers, R.; James, D.E. Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol.
Cell Biol. 2002, 3, 267–277. [CrossRef] [PubMed]
43. Zisman, A.; Peroni, O.D.; Abel, E.D.; Michael, M.D.; Mauvais-Jarvis, F.; Lowell, B.B.; Wojtaszewski, J.F.;
Hirshman, M.F.; Virkamaki, A.; Goodyear, L.J.; et al. Targeted disruption of the glucose transporter
4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. 2000, 6, 924–928.
[PubMed]
44. Zhao, F.Q.; Keating, A.F. Expression and regulation of glucose transporters in the bovine mammary gland.
J. Dairy Sci. 2007, 90, 76–86. [CrossRef] [PubMed]
45. Fujita, H.; Hatakeyama, H.; Watanabe, T.M.; Sato, M.; Higuchi, H.; Kanzaki, M. Identification of three distinct
functional sites of insulin-mediated GLUT4 trafficking in adipocytes using quantitative single molecule
imaging. Mol. Biol. Cell 2010, 21, 2721–2731. [CrossRef] [PubMed]
46. Cai, H.; Reinisch, K.; Ferro-Novick, S. Coats, tethers, Rabs, and SNAREs work together to mediate the
intracellular destination of a transport vesicle. Dev. Cell 2007, 12, 671–682. [CrossRef] [PubMed]
47. Leto, D.; Saltiel, A.R. Regulation of glucose transport by insulin: Traffic control of GLUT4. Nat. Rev. Mol. Cell
Biol. 2012, 13, 383–396. [CrossRef] [PubMed]
48. Nolan, J.H.; Jeffrey, S.E. Signaling, cytoskeletal and membrane mechanisms regulating GLUT4 exocytosis.
Trends Endocrinol. Metab. 2011, 22, 110–116.
49. Feener, E.P.; Backer, J.M.; King, G.L.; Wilden, P.A.; Sun, X.J.; Kahn, C.R.; White, M.F. Insulin stimulates serine
and tyrosine phosphorylation in the juxtamembrane region of the insulin receptor. J. Biol. Chem. 1993, 268,
11256–11264. [PubMed]
50. White, M.F.; Kahn, C.R. The insulin signaling system. J. Biol. Chem. 1994, 269, 1–5. [PubMed]
51. Saltiel, A.R.; Pessin, J.E. Insulin signaling in microdomains of the plasma membrane. Traffic 2003, 4, 711–716.
[CrossRef] [PubMed]
52. McClain, D.A.; Maegawa, H.; Lee, J.; Dull, T.J.; Ulrich, A.; Olefsky, J.M. A mutant insulin receptor with
defective tyrosine kinase displays no biological activity and does not undergo endocytosis. J. Biol. Chem.
1987, 262, 14663–14671. [PubMed]
53. Whiteman, E.L.; Cho, H.; Birnbaun, M.J. Role of Akt/protein kinase B in metabolism. Trends Endocrinol. Metab.
2002, 13, 444–451. [CrossRef]
54. Gonzalez, E.; McGraw, T.E. Insulin signaling diverges into Akt-dependent and -independent signals to
regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane. Mol. Biol. Cell
2006, 17, 4484–4493. [CrossRef] [PubMed]
55. Chen, X.W.; Leto, D.; Xiong, T.; Yu, G.; Cheng, A.; Decker, S.; Saltiel, A.R. A Ral GAP complex links PI
3-kinase/Akt signaling to RalA activation in insulin action. Mol. Biol. Cell 2011, 22, 141–152. [CrossRef]
[PubMed]
56. Min, J.; Okada, S.; Kanzaki, M.; Elmendorf, J.S.; Coker, K.J.; Ceresa, B.P.; Syu, L.J.; Noda, Y.; Saltiel, A.R.;
Pessin, J.E. Synip: A novel insulin-regulated syntaxin 4-binding protein mediating GLUT4 translocation in
adipocytes. Mol. Cell. 1999, 3, 751–760. [CrossRef]
57. Katome, T.; Obata, T.; Matsushima, R.; Masuyama, N.; Cantley, L.C.; Gotoh, Y.; Kishi, K.; Shiota, H.; Ebina, Y.
Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of
AKT/protein kinase B isoforms in insulin actions. J. Biol. Chem. 2003, 278, 28312–28323. [CrossRef] [PubMed]
58. Clarke, J.F.; Young, P.W.; Yonezawa, K.; Kasuga, M.; Holman, G.D. Inhibition of the translocation of GLUT1
and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem. J. 1994, 300,
631–635. [CrossRef] [PubMed]
59. Kohn, A.D.; Summers, S.A.; Birnbaum, M.J.; Roth, R.A. Expression of a constitutively active Akt Ser/Thr
kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem.
1996, 271, 31372–31378. [CrossRef] [PubMed]
60. Ng, Y.; Ramm, G.; Lopez, J.A.; James, D.E. Rapid activation of Akt2 is sufficient to stimulate GLUT4
translocation in 3T3-L1 adipocytes. Cell Metab. 2008, 7, 348–356. [CrossRef] [PubMed]
61. Bai, L.; Wang, Y.; Fan, J.; Chen, Y.; Ji, W.; Qu, A.; Xu, P.; James, D.E.; Xu, T. Dissecting multiple steps of
GLUT4 trafficking and identifying the sites of insulin action. Cell Metab. 2007, 5, 47–57. [CrossRef] [PubMed]
62. Yamada, E.; Okada, S.; Saito, T.; Ohshima, K.; Sato, M.; Tsuchiya, T.; Uehara, Y.; Shimizu, H.; Mori, M. Akt2
phosphorylates Synip to regulate docking and fusion of GLUT4-containing vesicles. J. Cell Biol. 2005, 168,
921–928. [CrossRef] [PubMed]
Molecules 2018, 23, 258 14 of 15
63. Ribon, V.; Printen, J.A.; Hoffman, N.G.; Kay, B.K.; Saltiel, A.R. A novel, multifuntional c-Cbl binding protein
in insulin receptor signaling in 3T3-L1 adipocytes. Mol. Cell. Biol. 1998, 18, 872–879. [CrossRef]
64. Liu, J.; Kimura, A.; Baumann, C.A.; Saltiel, A.R. APS facilitates c-Cbl tyrosine phosphorylation and GLUT4
translocation in response to insulin in 3T3-L1 adipocytes. Mol. Cell. Biol. 2002, 22, 3599–3609. [CrossRef]
[PubMed]
65. Ribon, V.; Hubbell, S.; Herrera, R.; Saltiel, A.R. The product of the cbl oncogene forms stable complexes
in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner. Mol. Cell. Biol. 1996, 16,
45–52. [CrossRef] [PubMed]
66. Knudsen, B.S.; Feller, S.M.; Hanafusa, H. Four proline-rich sequences of the guanine-nucleotide exchange
factor C3G bind with unique specificity to the first Src homology 3 domain of Crk. J. Biol. Chem. 1994, 269,
32781–32787. [PubMed]
67. Chiang, S.H.; Baumann, C.A.; Kanzaki, M.; Thurmond, D.C.; Watson, R.T.; Neudauer, C.L.; Macara, I.G.;
Pessin, J.E.; Saltiel, A.R. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of
TC10. Nature 2001, 410, 944–948. [CrossRef] [PubMed]
68. Chang, L.; Chiang, S.H.; Saltiel, A.R. TC10α is required for insulin-stimulated glucose uptake in adipocytes.
Endocrinology 2007, 148, 27–33. [CrossRef] [PubMed]
69. Ribon, V.; Johnson, J.H.; Camp, H.S.; Saltiel, A.R. Thiazolidinediones and insulin resistance: Peroxisome
proliferator activated receptor gamma activation stimulates expression of the CAP gene. Proc. Natl. Acad.
Sci. USA 1998, 95, 14751–14756. [CrossRef]
70. Mitra, P.; Zheng, X.; Czech, M.P. RNAi-based analysis of CAP, Cbl, and CrkII function in the regulation of
GLUT4 by insulin. J. Biol. Chem. 2004, 279, 37431–37435. [CrossRef] [PubMed]
71. Zhou, Q.Á.; Park, J.G.; Jiang, Z.Y.; Holik, J.J.; Mitra, P.; Semiz, S.; Guilherme, A.; Powelka, A.M.; Tang, X.;
Virbasius, J.; et al. Analysis of insulin signalling by RNAi-based gene silencing. Biochem. Soc. Trans. 2004, 32,
817–821. [CrossRef] [PubMed]
72. Tian, L.Y.; Bai, X.; Chen, X.H.; Fang, J.B.; Liu, S.H.; Chen, J.C. Anti-diabetic effect of methylswertianin
and bellidifolin from Swertia punicea Hemsl. and its potential mechanism. Phytomedicine 2010, 17, 533–539.
[CrossRef] [PubMed]
73. Naowaboot, J.; Pannangpetch, P.; Kukongviriyapan, V.; Prawan, A.; Kukongviriyapan, U.; Itharat, A.
Mulberry leaf extract stimulates glucose uptake and GLUT4 translocation in rat adipocytes. Am. J. Chin. Med.
2012, 40, 163–175. [CrossRef] [PubMed]
74. Baldea, L.A.N.; Martineau, L.C.; Benhaddou-Andaloussi, A.; Arnason, J.T.; Lévy, É.; Haddad, P.S. Inhibition
of intestinal glucose absorption by anti-diabetic medicinal plants derived from the James Bay Cree traditional
pharmacopeia. J. Ethnopharmacol. 2010, 132, 473–482. [CrossRef] [PubMed]
75. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A.L.; Normandin, D.; Cheng, A.;
Himms-Hagen, J.; Chan, C.C.; et al. Increased insulin sensitivity and obesity resistance in mice lacking the
protein tyrosine phosphatase-1B gene. Science 1999, 283, 1544–1548. [CrossRef] [PubMed]
76. Arya, A.; Looi, C.Y.; Wong, W.F.; Noordin, M.I.; Nyamathulla, S.; Mustafa, M.R.; Mohd, M.A. In vitro
antioxidant, PTP-1B inhibitory effects and in vivo hypoglycemic potential of selected medicinal plants.
Int. J. Pharmacol. 2013. [CrossRef]
77. Zhang, W.; Hong, D.; Zhou, Y.; Zhang, Y.; Shen, Q.; Li, J.Y.; Hu, L.H.; Li, J. Ursolic acid and its derivative
inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose
uptake. Biochim. Biophys. Acta 2006, 1760, 1505–1512. [CrossRef] [PubMed]
78. Zhang, Y.N.; Zhang, W.; Hong, D.; Shi, L.; Shen, Q.; Li, J.Y.; Li, J.; Hu, L.H. Oleanolic acid and its derivatives:
New inhibitor of protein tyrosine phosphatase 1B with cellular activities. Bioorg. Med. Chem. 2008, 16,
8697–8705. [CrossRef] [PubMed]
79. Zhang, B.; Salituro, G.; Szalkowski, D.; Li, Z.; Zhang, Y.; Royo, I.; Vilella, D.; D
Molecules 2018, 23, x FOR PEER REVIEW  15 of 15 
 
87. Xie, W.; Tanabe, G.; Matsuoka, K.; Amer, M.F.; Minematsu, T.; Wu, X.; Yoshikawa, M.; Muraoka, O. Role 
of the side chain stereochemistry in the α-glucosidase inhibitory activity of kotalanol, a potent natural α-
glucosidas  inhibitor. Bioorg. Med. Chem. 2011, 19, 2252–2262. 
88. Muraoka, O.; Morikawa, T.; Miyake, S.; Akaki, J.; Ninomiya, K.; Yoshikawa, M. Quantitative determination 
of potent α-glucosidase inhibitors, salacinol and kotalanol, in Salacia species using liquid chromatography-
mass sp ctrometry. J. Pharmaceut. Biomed. 2010, 52, 770–773. 
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
ı́ ez, M.T.; Pelaez, F.; Ruby, C.;
et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 284,
974–977. [CrossRef] [PubMed]
80. Lin, B.; Li, Z.; Park, K.; Deng, L.; Pai, A.; Zhong, L.; Pirrung, M.C.; Webster, N.J. Identification of novel orally
available small molecule insulin mimetics. J. Pharmacol. Exp. Ther. 2007, 323, 579–585. [CrossRef] [PubMed]
81. Arya, A.; Al-Obaidi, M.M.J.; Shahid, N.; Noordin, M.I.B.; Looi, C.Y.; Wong, W.F.; Khaing, S.L.; Mustafa, M.R.
Synergistic effect of quercetin and quinic acid by alleviating structural degeneration in the liver, kidney and
Molecules 2018, 23, 258 15 of 15
pancreas tissues of STZ-induced diabetic rats: A mechanistic study. Food Chem. Toxicol. 2014, 71, 183–196.
[CrossRef] [PubMed]
82. Taha, H.; Arya, A.; Paydar, M.; Looi, C.Y.; Wong, W.F.; Murthy, C.V.; Noordin, M.I.; Ali, H.M.; Mustafa, A.M.;
Hadi, A.H.A. Upregulation of insulin secretion and downregulation of pro-inflammatory cytokines, oxidative
stress and hyperglycemia in STZ-nicotinamide-induced type 2 diabetic rats by Pseuduvaria monticola bark
extract. Food Chem. Toxicol. 2015. [CrossRef] [PubMed]
83. Arya, A.; Al-Obaidi, M.M.J.; Karim, R.B.; Taha, H.; Khan, A.K.; Shahid, N.; Sayem, A.S.; Looi, C.Y.;
Mustafa, M.R.; Mohd, M.A.; Ali, H.M. Extract of Woodfordia fruticosa flowers ameliorates hyperglycemia,
oxidative stress and improves β-cell function in streptozotocin-nicotinamide induced diabetic rat.
J. Ethnopharmacol. 2015, 175, 229–240. [CrossRef] [PubMed]
84. Coman, C.; Rugina, O.D.; Socaciu, C. Plants and natural compounds with antidiabetic action. Not. Bot. Horti
Agrobot. Cluj-Napoca 2012, 40, 314.
85. Kim, K.J.; Lee, M.S.; Jo, K.; Hwang, J.K. Piperidine alkaloids from Piper retrofractum Vahl. protect against
high-fat diet-induced obesity by regulating lipid metabolism and activating AMP-activated protein kinase.
Biochem. Biophys. Res. Commun. 2011, 411, 219–225. [CrossRef] [PubMed]
86. Gunawan-Puteri, M.D.; Kawabata, J. Novel α-glucosidase inhibitors from Macaranga tanarius leaves.
Food Chem. 2010, 123, 384–389. [CrossRef]
87. Xie, W.; Tanabe, G.; Matsuoka, K.; Amer, M.F.; Minematsu, T.; Wu, X.; Yoshikawa, M.; Muraoka, O. Role
of the side chain stereochemistry in the α-glucosidase inhibitory activity of kotalanol, a potent natural
α-glucosidase inhibitor. Bioorg. Med. Chem. 2011, 19, 2252–2262. [CrossRef] [PubMed]
88. Muraoka, O.; Morikawa, T.; Miyake, S.; Akaki, J.; Ninomiya, K.; Yoshikawa, M. Quantitative determination of
potent α-glucosidase inhibitors, salacinol and kotalanol, in Salacia species using liquid chromatography-mass
spectrometry. J. Pharmaceut. Biomed. 2010, 52, 770–773. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
